In8Bio INAB
NASDAQ INAB
$1.40 +0.07 (+5.26%)
At close: Oct 1, 2026 · 4:00 PM EDT

In8Bio (INAB) Restructuring Costs (2024)

Updated

In8Bio's Restructuring Costs was $1.07 million in FY2024.

Analysis

In8Bio (INAB) Restructuring Costs (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 In8Bio 25.89 Mn 25.89 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 1.07 Mn
API Access

In8Bio Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=INAB&period=max&api_key=YOUR_API_KEY